Grifols' factor IX concentrates: New findings in biochemical characteristics and safety profiles

Haemophilia

Volumn 16, Issue SUPPL. 6, 2010, Pages 3-8

  Herring, Steven ^a  

^a Grifols SA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9 CONCENTRATE; FACTOR IX GRIFOLS; UNCLASSIFIED DRUG;

BLEEDING; DRUG MANUFACTURE; DRUG PURITY; DRUG SAFETY; HEMOPHILIA B; NUCLEIC ACID AMPLIFICATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REVIEW;

BLOOD COAGULATION FACTORS; BLOOD PROTEINS; CHROMATOGRAPHY; FACTOR IX; HEMOPHILIA B; HUMANS; VIRUSES;

EID: 77954632410     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02299.x     Document Type: Review

References (10)

1. Aggeler PM. Physiological basis for transfusion therapy in hemorrhagic disorders: a critical review. Transfusion 1961, 1:71-86.
2. Chistolini A, Mazzucconi MG, Tirindelli MC, La Verde G, Ferrari A, Mandelli F. Disseminated intravascular coagulation and myocardial infarction in a haemophilia B patient during therapy with prothrombin complex concentrates. Acta Haematol 1990, 83:163-5.
3. Conlan MG, Hoots WK. Disseminated intravascular coagulation and hemorrhage in hemophilia B following elective surgery. Am J Hematol 1990, 35:203-7.
4. Farrugia A, Evers T, Falcou PF, Burnouf T, Amorim L, Thomas S. Plasma fractionation issues. Biologicals 2009, 37:88-93.
5. Horowitz B, Wiebe ME, Lippin A, Stryker MH. Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations. Transfusion 1985, 25:516-22.
6. Caballero S, Belda F, Otegul M, Diez JM, Gajardo R, Jorquera JI. Effective removal of a TSE-model agent during FVIII/VWF purification. J Thromb Haemost 2009, 7(Suppl. 2). Abstract number: PP-WE-576
7. Diez JM, Caballero S, Belda FJ, Gajardo R, Jorquera JI. Elimination capacity of a TSE-model agent in the manufacturing process of Alphanate®/Fanhdi®, a human factor VIII/VWF complex concentrate. Haemophilia 2009, 15:1249-57.
8. Tateishi J, Kitamoto T, Mohri S. Scrapie removal using Planova virus removal filters. Biologicals 2001, 29:17-25.
9. Cartwright T. The elimination of viral contaimination risks. Protein Purification Techniques A Practical Approach Second Edition 2001, 66-71. Roe S. In, ed, New York, Oxford University Press USA
10. The design, contribution and interpretation of studies validating the inactivation and removal of viruses. 1995, Committee for Proprietary Medicinal Products (CPMP), CPMP/BWP/268/95